Prandial insulin was required in eight patients at 3 months and in five patients at 6 months after switching to semaglutide compared to 12 patients at baseline
Most gastrointestinal symptoms are mild to moderate and can be addressed through practical dietary and lifestyle modifications
involved in insulin release and the feeling of fullness
OBR, administered orally, downregulated the renal expression of URAT1, GLUT9, NOD-like receptor 3 (NLRP3), and other factors at both mRNA and protein levels, showcasing its potential as a therapeutic agent
Armed with this knowledge, youre now better prepared to start your treatment with confidence, knowing that any minor discomfort is just a step towards your health goals.
Highlights of Prescribing Information: Wegovy (semaglutide) injection, for subcutaneous use, tablets, for oral use